Roche's ocrelizumab meets in Phase III PPMS trial

Roche (SIX:ROG; OTCQX:RHHBY) said ocrelizumab ( RG1594) met the primary endpoint of reducing the progression of clinical disability for at least 12 weeks vs. placebo in the Phase III ORATORIO trial to treat primary progressive multiple sclerosis (MS).

The primary endpoint was measured by the Expanded Disability Status Scale (EDSS). Top-line data from the 732-patient trial will be presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Barcelona on Oct. 10. ...